pSivida Corp

Press Releases

All Releases
View Summary pSivida Announces Pricing of $16 Million Public Offering of Common Stock
Jan 7, 2016
PDF 14.3 KB Add to Briefcase
View Summary pSivida Announces Proposed Public Offering of Common Stock
Jan 6, 2016
PDF 14.8 KB Add to Briefcase
View Summary pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 28, 2015
PDF 20.6 KB Add to Briefcase
View Summary pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Dec 22, 2015
PDF 27.6 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Nov 5, 2015
PDF 32.6 KB Add to Briefcase
View Summary pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
Oct 30, 2015
PDF 14.4 KB Add to Briefcase
View Summary pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
Sep 28, 2015
PDF 16.7 KB Add to Briefcase
View Summary pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Sep 14, 2015
PDF 16.2 KB Add to Briefcase
View Summary pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results
Sep 9, 2015
PDF 32.7 KB Add to Briefcase
View Summary pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation's BioInterface 2015 Annual Symposium
Sep 3, 2015
PDF 16.4 KB Add to Briefcase
View Summary pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Sep 2, 2015
PDF 17.1 KB Add to Briefcase
View Summary pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend
Jul 21, 2015
PDF 17.3 KB Add to Briefcase
View Summary pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis
Jul 13, 2015
PDF 21.3 KB Add to Briefcase
View Summary pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
Jul 7, 2015
PDF 18.8 KB Add to Briefcase
View Summary pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015
Jun 24, 2015
PDF 17.3 KB Add to Briefcase
View Summary pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis
May 19, 2015
PDF 19.6 KB Add to Briefcase
View Summary pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
May 12, 2015
PDF 15.6 KB Add to Briefcase
View Summary pSivida Corp. Reports Third Quarter FY 2015 Results
May 8, 2015
PDF 31.2 KB Add to Briefcase
View Summary pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
May 1, 2015
PDF 16.4 KB Add to Briefcase
View Summary pSivida Corp. Reports ILUVIEN® for DME Approved in Poland
Apr 14, 2015
PDF 15.8 KB Add to Briefcase
Showing 41-60 of 275 Page: 1 2 3 4 5 6 7 ... 14  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Search Investor Relations

pSivida